# BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

> **NCT02706691** · PHASE2 · TERMINATED · sponsor: **University of Chicago** · enrollment: 1 (actual)

## Conditions studied

- FGFR Gene Amplification
- FGFR1 Gene Amplification
- FGFR2 Gene Amplification
- FGFR2 Gene Mutation
- FGFR3 Gene Mutation
- Head and Neck Squamous Cell Carcinoma
- Human Papillomavirus Infection
- Recurrent Head and Neck Carcinoma
- Recurrent Nasopharynx Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma

## Interventions

- **DRUG:** BGJ398

## Key facts

- **NCT ID:** NCT02706691
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-01
- **Primary completion:** 2019-02-11
- **Final completion:** 2019-02-11
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study stopped due to poor enrollment.
- **Last updated:** 2019-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02706691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02706691, "BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02706691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*